• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.29% Nasdaq Down3.25%

    Cempra, Inc. (CEMP)

    18.61 Up 0.60(3.33%) Feb 5, 4:00PM EST
    |After Hours : 18.68 Up 0.07 (0.38%) Feb 5, 5:27PM EST
    ProfileGet Profile for:
    Cempra, Inc.
    6320 Quadrangle Drive
    Suite 360
    Chapel Hill, NC 27517
    United States - Map
    Phone: 919-313-6601
    Website: http://www.cempra.com

    Index Membership:N/A
    Full Time Employees:55

    Business Summary 

    Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates include solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community acquired bacterial pneumonia, as well as for uncomplicated bacterial urethritis; and Taksta (CEM-102), an antibiotic that has completed Phase II clinical trials for refractory bone and joint infections. The company also produces novel macrolides for non-antibiotic uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cempra, Inc.

    Corporate Governance 
    Cempra, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 8. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 9; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Prabhavathi B. Fernandes Ph.D., 67
    Founder, Chief Exec. Officer, Pres and Director
    Mr. Mark W. Hahn , 53
    Chief Financial Officer and Exec. VP
    Mr. David S. Moore , 42
    Chief Commercialization Officer and Exec. VP
    Mr. Shane Barton ,
    Chief Accounting Officer, Sec. and Controller
    Mr. Kenneth Eheman Jr.,
    Legal Counsel
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders